Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

MLA

Badar, Talha, et al. “Survival of TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplantation after First Induction or Salvage Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).” Leukemia, vol. 37, no. 4, Apr. 2023, pp. 799–806. EBSCOhost, https://doi.org/10.1038/s41375-023-01847-7.

APA

Badar, T., Atallah, E., Shallis, R., Saliba, A. N., Patel, A., Bewersdorf, J. P., Grenet, J., Stahl, M., Duvall, A., Burkart, M., Palmisiano, N., Bradshaw, D., Kubiak, M., Dinner, S., Goldberg, A. D., Abaza, Y., Murthy, G. S. G., Kota, V., & Litzow, M. R. (2023). Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia, 37(4), 799–806. https://doi.org/10.1038/s41375-023-01847-7

Chicago

Badar, Talha, Ehab Atallah, Rory Shallis, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Justin Grenet, et al. 2023. “Survival of TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplantation after First Induction or Salvage Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).” Leukemia 37 (4): 799–806. doi:10.1038/s41375-023-01847-7.